X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13253) 13253
Book Review (1224) 1224
Publication (413) 413
Newsletter (220) 220
Conference Proceeding (21) 21
Newspaper Article (8) 8
Book Chapter (4) 4
Dissertation (4) 4
Magazine Article (3) 3
Report (2) 2
Transcript (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (12096) 12096
humans (11920) 11920
etoposide - administration & dosage (9160) 9160
male (7993) 7993
antineoplastic combined chemotherapy protocols - therapeutic use (7957) 7957
female (7565) 7565
oncology (6377) 6377
middle aged (6193) 6193
adult (6055) 6055
etoposide (4861) 4861
aged (4518) 4518
chemotherapy (4298) 4298
cisplatin - administration & dosage (4045) 4045
antineoplastic combined chemotherapy protocols - adverse effects (2895) 2895
treatment outcome (2891) 2891
cyclophosphamide - administration & dosage (2813) 2813
cancer (2585) 2585
combined modality therapy (2524) 2524
antineoplastic combined chemotherapy protocols - administration & dosage (2412) 2412
lung neoplasms - drug therapy (2410) 2410
adolescent (2405) 2405
doxorubicin - administration & dosage (2306) 2306
vincristine - administration & dosage (2152) 2152
hematology (2068) 2068
cisplatin (2003) 2003
etoposide - adverse effects (1928) 1928
drug administration schedule (1824) 1824
carboplatin - administration & dosage (1730) 1730
prognosis (1629) 1629
remission induction (1596) 1596
survival rate (1568) 1568
child (1404) 1404
bleomycin - administration & dosage (1403) 1403
cytarabine - administration & dosage (1388) 1388
survival analysis (1349) 1349
ifosfamide - administration & dosage (1345) 1345
disease-free survival (1325) 1325
neoplasm staging (1322) 1322
carcinoma, small cell - drug therapy (1298) 1298
therapy (1276) 1276
retrospective studies (1207) 1207
etoposide - therapeutic use (1171) 1171
child, preschool (1098) 1098
follow-up studies (1095) 1095
cyclophosphamide (1090) 1090
methotrexate - administration & dosage (1038) 1038
abridged index medicus (1007) 1007
carboplatin (1004) 1004
care and treatment (979) 979
carcinoma (915) 915
lung neoplasms - pathology (907) 907
animals (903) 903
prednisone - administration & dosage (901) 901
aged, 80 and over (888) 888
transplantation (881) 881
dose-response relationship, drug (879) 879
pharmacology & pharmacy (859) 859
trial (813) 813
infant (809) 809
survival (808) 808
tumors (802) 802
radiotherapy (798) 798
salvage therapy (789) 789
cisplatin - adverse effects (788) 788
transplantation, autologous (765) 765
antineoplastic agents - administration & dosage (764) 764
carcinoma, non-small-cell lung - drug therapy (749) 749
prospective studies (735) 735
recurrence (721) 721
time factors (721) 721
antineoplastic agents, phytogenic - administration & dosage (712) 712
doxorubicin (695) 695
hematopoietic stem cell transplantation (693) 693
lung neoplasms - mortality (690) 690
administration, oral (687) 687
medicine & public health (671) 671
combination chemotherapy (670) 670
research (668) 668
testicular neoplasms - drug therapy (666) 666
phase-ii (664) 664
children (641) 641
etoposide - pharmacology (639) 639
lymphoma, non-hodgkin - drug therapy (638) 638
vinblastine - administration & dosage (627) 627
young adult (627) 627
pediatrics (606) 606
bone-marrow transplantation (602) 602
chemotherapy, adjuvant (581) 581
lung neoplasms - radiotherapy (563) 563
risk factors (562) 562
toxicity (561) 561
ifosfamide (560) 560
antineoplastic agents - therapeutic use (552) 552
mice (551) 551
cyclophosphamide - adverse effects (533) 533
infusions, intravenous (529) 529
apoptosis (514) 514
bone marrow transplantation (514) 514
high-dose chemotherapy (511) 511
paclitaxel - administration & dosage (511) 511
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11963) 11963
Japanese (907) 907
German (159) 159
French (146) 146
Chinese (102) 102
Spanish (61) 61
Russian (44) 44
Polish (39) 39
Italian (23) 23
Hungarian (16) 16
Dutch (6) 6
Serbian (6) 6
Czech (4) 4
Hebrew (3) 3
Portuguese (3) 3
Danish (2) 2
Korean (2) 2
Ukrainian (2) 2
Bulgarian (1) 1
Croatian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 04/2016, Volume 34, Issue 11, pp. 1175 - 1181
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2016, Volume 34, Issue 17, pp. 2020 - 2027
Journal Article
The Lancet Oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1076 - 1088
The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated... 
CLINICAL-PRACTICE GUIDELINES | SURVIVAL | SUPPORT | IMPACT | CONSOLIDATION | RESPONSE CRITERIA | ONCOLOGY | R-CHOP | NON-HODGKIN-LYMPHOMA | ELDERLY-PATIENTS | MEGACHOEP | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Consolidation Chemotherapy | Cyclophosphamide - adverse effects | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Intention to Treat Analysis | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Stem Cell Transplantation - adverse effects | Stem cells | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 12, pp. 1188 - 1194
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2017, Volume 35, Issue 16, pp. 1786 - 1794
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2013, Volume 368, Issue 15, pp. 1408 - 1416
A dose-intense infusional chemotherapy program plus rituximab had a high degree of efficacy in patients with primary mediastinal B-cell lymphoma, which is... 
MEDICINE, GENERAL & INTERNAL | AMPLIFICATION | MANAGEMENT | EFFICACY | DOXORUBICIN | SCLEROSIS | CLASSICAL HODGKIN LYMPHOMA | RADIOTHERAPY | EXPRESSION | GERMINAL-CENTER | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Filgrastim | Dose-Response Relationship, Drug | Young Adult | Vincristine - administration & dosage | Adult | Female | Retrospective Studies | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Kaplan-Meier Estimate | Rituximab | Stroke Volume - drug effects | Etoposide - administration & dosage | Recombinant Proteins - administration & dosage | Disease-Free Survival | Vincristine - adverse effects | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Granulocyte Colony-Stimulating Factor - administration & dosage | Drugs | Dose-response relationship (Biochemistry) | Usage | Cyclophosphamide | Patient outcomes | Dosage and administration | Lymphomas | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | Doxorubicin | Medical research | Nuclear magnetic resonance--NMR | Disease | Review boards | Genes | Etoposide | Prednisone | Radiation therapy | Kinases | Vincristine | Lymphoma | Patients | Morbidity | Chemotherapy | Lymphocytes B | Remission | Mutation | Hodgkin's disease | B-cell lymphoma | Index Medicus | Abridged Index Medicus
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2014, Volume 165, Issue 4, pp. 534 - 544
The purpose of this national retrospective study was to evaluate the outcome in children with relapsed or primary refractory Hodgkin lymphoma [ HL ] after a... 
refractory disease | relapse | children | odgkin lymphoma | survival | Relapse | Children | Refractory disease | Survival | Hodgkin lymphoma | COMBINED-MODALITY THERAPY | PROGNOSTIC-FACTORS | RADIATION | CHEMOTHERAPY | TRIAL | FRENCH SOCIETY | DISEASE | SALVAGE THERAPY | RADIOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Procarbazine - administration & dosage | Prednisolone - adverse effects | Recurrence | Cyclophosphamide - administration & dosage | Prednisolone - administration & dosage | Follow-Up Studies | Humans | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Hodgkin Disease - surgery | Hodgkin Disease - mortality | Vincristine - administration & dosage | Child | Dacarbazine - administration & dosage | Dexamethasone - administration & dosage | Hematopoietic Stem Cell Transplantation | Etoposide - administration & dosage | Combined Modality Therapy | Bleomycin - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Ifosfamide - administration & dosage | Adolescent | Vincristine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Cisplatin - administration & dosage | Hodgkin Disease - radiotherapy | Multicenter Studies as Topic | Hodgkin Disease - drug therapy | Retrospective Studies | Radiotherapy, Adjuvant | Doxorubicin - administration & dosage | Chlorambucil - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Ifosfamide - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Clinical Trials as Topic | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Carmustine - administration & dosage | Patient outcomes | Diseases | Index Medicus
Journal Article
Annals of Oncology, ISSN 0923-7534, 03/2011, Volume 22, Issue 3, pp. 664 - 670
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 05/2012, Volume 119, Issue 20, pp. 4619 - 4624
Approximately 5-10% of diffuse large B-cell lymphomas (DLBCL) harbor a 8q24/MYC rearrangement (MYC+). We determined the prognostic significance of MYC... 
REARRANGEMENT | IMPACT | POOR-PROGNOSIS | T(14/18) | IN-SITU HYBRIDIZATION | CLASSIFICATION | HEMATOLOGY | EXPRESSION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Podophyllotoxin - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Transplantation, Autologous | Cytarabine - adverse effects | Cisplatin - administration & dosage | Young Adult | Lymphoma, Large B-Cell, Diffuse - therapy | Melphalan - adverse effects | Immunotherapy | Treatment Failure | Podophyllotoxin - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Carmustine - adverse effects | Genes, myc - physiology | Dexamethasone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Ifosfamide - adverse effects | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Cytarabine - administration & dosage | Lymphoma, Large B-Cell, Diffuse - mortality | Melphalan - administration & dosage | Ifosfamide - administration & dosage | Cisplatin - adverse effects | Aged | Hematopoietic Stem Cell Transplantation - methods | Antibodies, Monoclonal, Murine-Derived - adverse effects | Lymphoma, Large B-Cell, Diffuse - genetics | Carmustine - administration & dosage | Index Medicus | Abridged Index Medicus | Life Sciences | Biochemistry, Molecular Biology | Lymphoma, Large B-Cell, Diffuse | Podophyllotoxin | methods | Genes, myc | Cytarabine | genetics | administration & dosage | Melphalan | Antibodies, Monoclonal, Murine-Derived | Dexamethasone | drug therapy | Ifosfamide | Carmustine | therapy | Antineoplastic Combined Chemotherapy Protocols | Etoposide | physiology | Hematopoietic Stem Cell Transplantation | Cisplatin | adverse effects | mortality | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 812 - 822
Summary Background Previous trials from our group suggested an overall survival benefit with five cycles of adjuvant full-dose epirubicin plus ifosfamide in... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | CRITERIA | THERAPY | RECIST | CLINICAL-TRIAL | HIGH-GRADE | ONCOLOGY | DOSE ADJUVANT CHEMOTHERAPY | EXTREMITIES | TUMOR RESPONSE ASSESSMENT | IFOSFAMIDE | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Trabectedin | Sarcoma - therapy | Young Adult | Neurilemmoma - therapy | Dioxoles - administration & dosage | Back | Adult | Neutropenia - chemically induced | Child | Extremities | Soft Tissue Neoplasms - therapy | Dacarbazine - administration & dosage | Thoracic Wall | Sarcoma, Synovial - therapy | Deoxycytidine - administration & dosage | Risk Factors | Docetaxel | Anemia - chemically induced | Etoposide - administration & dosage | Tetrahydroisoquinolines - administration & dosage | Thrombocytopenia - chemically induced | Abdominal Wall | Sarcoma - pathology | Leiomyosarcoma - therapy | Disease-Free Survival | Taxoids - administration & dosage | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - methods | Neoadjuvant Therapy - methods | Adolescent | Soft Tissue Neoplasms - pathology | Aged | Deoxycytidine - analogs & derivatives | Liposarcoma, Myxoid - therapy | Care and treatment | Anthracyclines | Sarcoma | Adjuvant treatment | Clinical trials | Product development | Standards | Cancer | Index Medicus
Journal Article